Solid-organ transplant immunosuppressant is kinds of drugs which reduce the strength of the body’s immune system in solid organ transplant. The drugs prevent the activity of the immune system used to inhibit the rejection of transplanted organs & tissues. When a person endures any transplantation, the body distinguishes the transplant as foreign tissue and attacks it, resulting in rejection. This type of drug dilutes the immune system, therefore reducing the reaction towards the transplant. These drugs help in the survival of many patients as well as improve the quality of life.
The major benefit of a solid organ transplant is the consent of the patient himself or the family of the patient. Organ harvesting without appropriate consent is an illegal and massive crime. It is frequently carried out with the brain dead patient whose other organs are healthy and can be used to protect another person’s life. The process needs to be done right after the death of a patient until a couple of hours. This procedure is implemented to treat organ failures in the liver, kidney, lungs, and many more. A kidney is the most commonly transplanted organ that is followed by the liver.
According to study, “World Solid Organ Transplant Immunosuppressant Market Research Report 2024(covering USA, EU, China, South East Asia, Japan and etc)” the key companies operating in the world solid organ transplant immunosuppressant market are Astellas Pharma Inc., NovartisInternational AG, Hoffmann-La Roche Ltd., GlaxoSmithKline, Bristol-Myers Squibb Company, Janssen Pharmaceutical, Abbvie Inc., Wyeth (Pfizer) Inc., Huadong Pharmaceutical, Genzyme (Sanofi), Veloxis Pharmaceuticals, Hisun, North China Pharmaceutical Huasheng Co., Cinkate Corporation, SL PHARM, Hongsheng, Nanjing Hicin, Sinopharm Chuan Kang Pharmaceutical, Wnsui, Huitian. The key players are highly focusing on offering branded & generic immunosuppressive therapies to increase their customer base. To retain their market shares, players are also trying to develop enhanced immunosuppressants.
Based on product type, solid organ transplant immunosuppressant market is segmented into chemical composition, biologics, and fungal products. Based on drugs type, the market is segmented into antibodies, calcineurin inhibitors, antiproliferative agents, steroids and mTOR inhibitors. Calcineurin inhibitors are further sub-segmented into cyclosporine and tacrolimus. mTOR inhibitor is also further sub-segmented into everolimus and sirolimus. Based on therapeutics, the market is segmented into a heart transplant, kidney transplant, lung transplant, and liver transplant. Based on commercialized products, the market is segmented into Zenapax, Cellcept, Prograf, Neoral, and Myfortic. In addition, based on application, the market is segmented into preoperative solid organ transplant immunosuppressant, postoperative solid organ transplant immunosuppressant and surgery solid organ transplant immunosuppressant.
The solid organ transplant immunosuppressant market is driven by a rise in the prevalence of chronic diseases & organ failure, followed by an increase in consumption of alcohol & an unhealthy diet, a rise in medical tourism, advancement in technology & immunosuppressant drug discovery, improvements in surgical techniques and rise in prevalence of renal diseases. However, the high cost of transplantation, an increase in the incident of organ failure and a limited number of the donor may impact the market.
Based on geography, USA country holds major share, followed by EU in solid organ transplant immunosuppressant market owing to rise in the number of successful organ replacement surgeries, rapid development in the medical sector and higher healthcare expenditure in the country. China’s country is expected to witness a higher growth rate due to growth in the number of transplantation procedures, an increase in population and a rise in the availability of developed infrastructure over the forecast period.
Global Solid Organ Transplant Immunosuppressant Market: Product Segment Analysis
Chemical composition
Fungal product
Biologics
Global Solid Organ Transplant Immunosuppressant Market: Application Segment Analysis
Solid Organ Transplant Immunosuppressant
Global Solid Organ Transplant Immunosuppressant Market: Regional Segment Analysis
USA
Europe
Japan
China
India
Southeast Asia
The players mentioned in our report:-
Astellas Pharma
Roche
Novartis
Wyeth (Pfizer)
GlaxoSmithKline
Genzyme (Sanofi)
Huadong Pharmaceutical
North China Pharmaceutical Huasheng Co.
Hisun
SL PHARM
Nanjing Hicin
Hongsheng
CINKATE CORPORATION
Wnsui
Huitian
SINOPHARM CHUAN KANG PHARMACEUTICAL
To Know More, Click On The Link Below:-
World Solid Organ Transplant Immunosuppressant Market
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
